These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 10201829)

  • 41. Design and synthesis of a novel synthetic NAPAP-penta-saccharide conjugate displaying a dual antithrombotic action.
    Buijsman RC; Basten JE; van Dinther TG; van der Marel GA; van Boeckel CA; van Boom JH
    Bioorg Med Chem Lett; 1999 Jul; 9(14):2013-8. PubMed ID: 10450972
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 1,2-Disubstituted indole, azaindole and benzimidazole derivatives possessing amine moiety: a novel series of thrombin inhibitors.
    Takeuchi K; Bastian JA; Gifford-Moore DS; Harper RW; Miller SC; Mullaney JT; Sall DJ; Smith GF; Zhang M; Fisher MJ
    Bioorg Med Chem Lett; 2000 Oct; 10(20):2347-51. PubMed ID: 11055353
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Benzamidine derivatives--relationship between antithrombin activity and structure.
    Walsmann P
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(1):75-82. PubMed ID: 6177612
    [No Abstract]   [Full Text] [Related]  

  • 44. [A new generation of anticoagulants: design, synthesis and pharmacologic profile of thrombin inhibtors].
    Schmid G; Ackermann J; Banner D; Gast A; Gubernator K; Hadváry P; Hilpert K; Labler L; Tschopp T
    J Pharm Belg; 1995; 50(2-3):188-93. PubMed ID: 7674118
    [No Abstract]   [Full Text] [Related]  

  • 45. New aromatic diamidines with central alpha-oxyalkane or alpha, omega-dioxyalkane chains. Structure-activity relationships for the inhibition of trypsin, pancreatic kallikrein, and thrombin and for the inhibition of the overall coagulation process.
    Geratz JD; Cheng MC; Tidwell RR
    J Med Chem; 1975 May; 18(5):477-81. PubMed ID: 1171238
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Protease inhibitors: Part 4. Synthesis of weakly basic thrombin inhibitors incorporating pyridinium-sulfanilylaminoguanidine moieties.
    Supuran CT; Briganti F; Scozzafava A; Ilies MA
    J Enzyme Inhib; 2000; 15(4):335-56. PubMed ID: 10995066
    [TBL] [Abstract][Full Text] [Related]  

  • 47. P3 optimization of functional potency, in vivo efficacy and oral bioavailability in 3-aminopyrazinone thrombin inhibitors bearing non-charged groups at the P1 position.
    Isaacs RC; Newton CL; Cutrona KJ; Mercer SP; Dorsey BD; McDonough CM; Cook JJ; Krueger JA; Lewis SD; Lucas BJ; Lyle EA; Lynch JJ; Miller-Stein C; Michener MT; Wallace AA; White RB; Wong BK
    Bioorg Med Chem Lett; 2011 Mar; 21(5):1532-5. PubMed ID: 21295466
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Design, synthesis, and biological activity of potent and selective inhibitors of blood coagulation factor Xa.
    Willardsen JA; Dudley DA; Cody WL; Chi L; McClanahan TB; Mertz TE; Potoczak RE; Narasimhan LS; Holland DR; Rapundalo ST; Edmunds JJ
    J Med Chem; 2004 Jul; 47(16):4089-99. PubMed ID: 15267248
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Preparation of L-proline based aeruginosin 298-A analogs: optimization of the P1-moiety.
    Wang G; Goyal N; Hopkinson B
    Bioorg Med Chem Lett; 2009 Jul; 19(14):3798-803. PubMed ID: 19447619
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Discovery of a novel, selective, and orally bioavailable class of thrombin inhibitors incorporating aminopyridyl moieties at the P1 position.
    Feng DM; Gardell SJ; Lewis SD; Bock MG; Chen Z; Freidinger RM; Naylor-Olsen AM; Ramjit HG; Woltmann R; Baskin EP; Lynch JJ; Lucas R; Shafer JA; Dancheck KB; Chen IW; Mao SS; Krueger JA; Hare TR; Mulichak AM; Vacca JP
    J Med Chem; 1997 Nov; 40(23):3726-33. PubMed ID: 9371237
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biliary excretion of synthetic benzamidine-type thrombin inhibitors in rabbits and rats.
    Hauptmann J; Kaiser B; Paintz M; Markwardt F
    Biomed Biochim Acta; 1987; 46(6):445-53. PubMed ID: 3675563
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Biochemical and crystallographic characterization of homologous non-peptidic thrombin inhibitors having alternate binding modes.
    Strickland CL; Fevig JM; Galemmo RA; Wells BL; Kettner CA; Weber PC
    Acta Crystallogr D Biol Crystallogr; 1998 Nov; 54(Pt 6 Pt 2):1207-15. PubMed ID: 10089499
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Molecular design and characterization of an alpha-thrombin inhibitor containing a novel P1 moiety.
    Malikayil JA; Burkhart JP; Schreuder HA; Broersma RJ; Tardif C; Kutcher LW; Mehdi S; Schatzman GL; Neises B; Peet NP
    Biochemistry; 1997 Feb; 36(5):1034-40. PubMed ID: 9033393
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Discovery of Benzamidine- and 1-Aminoisoquinoline-Based Human MAS-Related G-Protein-Coupled Receptor X1 (MRGPRX1) Agonists.
    Prchalová E; Hin N; Thomas AG; Veeravalli V; Ng J; Alt J; Rais R; Rojas C; Li Z; Hihara H; Aoki M; Yoshizawa K; Nishioka T; Suzuki S; Kopajtic T; Chatrath S; Liu Q; Dong X; Slusher BS; Tsukamoto T
    J Med Chem; 2019 Sep; 62(18):8631-8641. PubMed ID: 31498617
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Design and synthesis of potent and highly selective thrombin inhibitors.
    Hilpert K; Ackermann J; Banner DW; Gast A; Gubernator K; Hadváry P; Labler L; Müller K; Schmid G; Tschopp TB
    J Med Chem; 1994 Nov; 37(23):3889-901. PubMed ID: 7966150
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Novel potent and selective thrombin inhibitors based on a central 1,4-benzoxazin-3(4H)-one scaffold.
    Ilas J; Tomasić T; Kikelj D
    J Med Chem; 2008 May; 51(9):2863-7. PubMed ID: 18412326
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Structure-activity relationships of substituted benzothiophene-anthranilamide factor Xa inhibitors.
    Chou YL; Davey DD; Eagen KA; Griedel BD; Karanjawala R; Phillips GB; Sacchi KL; Shaw KJ; Wu SC; Lentz D; Liang AM; Trinh L; Morrissey MM; Kochanny MJ
    Bioorg Med Chem Lett; 2003 Feb; 13(3):507-11. PubMed ID: 12565961
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interactions of thrombin with benzamidine-based inhibitors.
    Stürzebecher J; Vieweg H; Wikström P; Turk D; Bode W
    Biol Chem Hoppe Seyler; 1992 Jul; 373(7):491-6. PubMed ID: 1515080
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Quantum chemical studies on substituted benzamidines as inhibitors of the serine proteinases trypsin and thrombin].
    Henkel HJ; Labes D; Hagen V
    Pharmazie; 1983 May; 38(5):342-6. PubMed ID: 6611634
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Crystal structure of human factor VIIa/tissue factor in complex with peptide mimetic inhibitor.
    Kadono S; Sakamoto A; Kikuchi Y; Oh-eda M; Yabuta N; Koga T; Hattori K; Shiraishi T; Haramura M; Kodama H; Esaki T; Sato H; Watanabe Y; Itoh S; Ohta M; Kozono T
    Biochem Biophys Res Commun; 2004 Nov; 324(4):1227-33. PubMed ID: 15504346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.